MASS-FIX (MALDI-TOF MS)
A groundbreaking approach to monoclonal protein identification
For patients at risk of plasma cell disorders, early identification is critical to ensure better outcomes. Coined as MASS-FIX, our innovative approach uses matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS), and marks the first major breakthrough in multiple myeloma screening since gel electrophoresis was developed in 1967.
By weighing M-proteins, we overcome electrophoresis’s limitations in detection and provide the most accurate understanding of a patient’s M-proteins. This novel testing also helps health care providers understand their patients’ risk of progression to multiple myeloma or amyloid light-chain (AL) amyloidosis. This level of insight is not possible with traditional testing methods.
The impact of MASS-FIX extends beyond the hematologic systems into renal and neurologic spheres. As more is learned about the molecular, cytogenic, and protein variations of M-protein disorders, clinicians have discovered additional disease associations. Learn more here.
The new MASS-FIX testing method provides:
DMOGA | Monoclonal Gammopathy, Diagnostic, Serum
Analytic time: 2 days
Appropriate ordering scenario
PEISO | Protein Electrophoresis and Isotype, Serum
Analytic time: 2 days
Appropriate ordering scenario
TMOGA | Monoclonal Gammopathy, Monitoring, Serum
Analytic time: Same day/1 day
Appropriate ordering scenario
Analytic time: Same day/1 day
Appropriate ordering scenario
How an ex-NFL linebacker overcame his greatest opponent, amyloidosis
Matt Millen, an ex-pro NFL player who played on four Super Bowl-winning teams, underwent a nearly six-year medical journey in search for answers. Finally, he was diagnosed with amyloidosis using a new testing methodology at Mayo Clinic.